China Archives

News and Trends 20 Jul 2023

Endometrial cancer drug receives breakthrough therapy designation in China

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

July 20, 2023 - 4 minutesmins - By Jim Cornall

In Depth 19 Jul 2023

Genetic engineering giants: is China poised to lead the way?

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

July 19, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 5 Jul 2023

Narcolepsy drug gets Chinese approval

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. In China, pitolisant is the first approved innovative drug for […]

July 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

July 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

Breakthrough treatment for skin infections?

A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

Clearance for anti-tumor bispecific antibody trial

TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […]

June 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 23 May 2023

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […]

May 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 May 2023

Researchers’ mutation discovery offers new Alzheimer’s hope

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […]

May 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 May 2023

Researchers overcome stem cell delivery issues

A recent study explains how researchers have devised a new method for delivering particles into stem cells, which are difficult to penetrate. The discovery will make it easier to direct and enhance the processes involved in regenerative medicine. Regenerative medicine takes advantage of the fact that our body’s stem cells can change into many other […]

May 9, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 20 Apr 2023

Hasten raises $315M for acquisitions and pipeline development

CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limited, have completed a $315 million fundraising round for Hasten. Hasten is a Chinese biopharma company backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City. The fundraising round was co-led by CBC and Abu Dhabi sovereign wealth […]

April 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

China

Endometrial cancer drug receives breakthrough therapy designation in China

Genetic engineering giants: is China poised to lead the way?

Narcolepsy drug gets Chinese approval

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Breakthrough treatment for skin infections?

Clearance for anti-tumor bispecific antibody trial

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

Researchers’ mutation discovery offers new Alzheimer’s hope

Researchers overcome stem cell delivery issues

Hasten raises $315M for acquisitions and pipeline development

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!